Secretagogin may not be a new neuroendocrine biomarker in schizophrenia while levels may reflect clinical severity

Erzin G., Topcuoglu C., Bayram S., Karadag H., ÖZKAYA G., Turhan T., ...More

PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY, vol.29, no.4, pp.394-398, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.1080/24750573.2019.1589175
  • Journal Name: PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.394-398
  • Keywords: Schizophrenia, neuroendocrine, peripheral markers, DORSOLATERAL PREFRONTAL CORTEX, NEGATIVE SYNDROME SCALE, INSULIN-SECRETION, GENE-EXPRESSION, NEURONS, RELIABILITY, VALIDITY, DEFICITS, GABA
  • Bursa Uludag University Affiliated: Yes

Abstract

OBJECTIVE: Schizophrenia is a neurodegenerative and neurodevelopmental disorder. For this reason, it is important to determine the level of markers that are neuroprotective and have been altered in other neurodegenerative diseases in inspecting the etiology of schizophrenia. Secretagogin (SCGN), is a member of Calcium (Ca) binding proteins and thought to have a neuroprotective effect. In this study, we aimed to compare the level of secretagogin (SCGN) between age and gender-matched schizophrenia and control group.